이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

EDAP TMS 과거 수익 실적

과거 기준 확인 0/6

EDAP TMS의 수입은 연평균 -72%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 8.7%의 비율로 증가했습니다. 매출은 연평균 8.4%의 비율로 증가해 왔습니다.

주요 정보

-72.0%

수익 성장률

-69.5%

EPS 성장률

Medical Equipment 산업 성장	8.9%
매출 성장률	8.4%
자기자본 수익률	-34.4%
순이익	-30.1%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

Mar 22

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

Aug 24

EDAP's Focal One Revenue Is Set To Accelerate

Aug 08

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

Jul 19

Acceleration At EDAP

Jan 11

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

Jan 06

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Nov 25

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Sep 07

EDAP's subsidiary names medTech industry veteran Ryan Rhodes as CEO

Jun 15

EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Apr 02

Analysts Are Betting On EDAP TMS S.A. (NASDAQ:EDAP) With A Big Upgrade This Week

Jan 24

Treatment with EDAP's HIFU ultrasound benefits in prostate cancer patients, study shows

Jan 14

New reimbursement rules for HIFU technology to favor EDAP TMS

Dec 09

EDAP TMS S.A. EPS misses by $0.02, beats on revenue

Nov 18

수익 및 비용 분석

EDAP TMS 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:EDAP 수익, 비용 및 수입 (EUR Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	61	-18	32	8
31 Dec 23	60	-21	34	7
30 Sep 23	57	-21	35	6
30 Jun 23	57	-17	33	6
31 Mar 23	57	-11	30	5
31 Dec 22	55	-3	24	5
30 Sep 22	53	4	21	4
30 Jun 22	51	3	20	4
31 Mar 22	47	0	18	4
31 Dec 21	44	1	17	3
30 Sep 21	45	0	15	4
30 Jun 21	45	0	14	4
31 Mar 21	44	0	13	4
31 Dec 20	42	-2	14	4
30 Sep 20	38	-3	14	4
30 Jun 20	39	-2	14	4
31 Mar 20	42	0	15	4
31 Dec 19	45	2	15	4
30 Sep 19	46	4	15	4
30 Jun 19	44	2	15	4
31 Mar 19	40	0	14	4
31 Dec 18	39	0	14	4
30 Sep 18	36	-1	13	4
30 Jun 18	35	-1	13	4
31 Mar 18	36	-2	13	4
31 Dec 17	36	-1	13	4
30 Sep 17	36	-2	13	4
30 Jun 17	37	0	13	4
31 Mar 17	36	4	12	4
31 Dec 16	36	4	12	4
30 Sep 16	37	10	12	3
30 Jun 16	35	4	11	3
31 Mar 16	35	2	11	3
31 Dec 15	32	-2	11	3
30 Sep 15	27	-9	10	3
30 Jun 15	27	2	10	3
31 Mar 15	25	-4	10	3
31 Dec 14	26	-1	10	3
30 Sep 14	28	2	10	3
30 Jun 14	27	-5	9	3
31 Mar 14	26	0	9	2
31 Dec 13	24	-5	9	3
30 Sep 13	25	-6	10	3

양질의 수익: EDAP 은(는) 현재 수익성이 없습니다.

이익 마진 증가: EDAP 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: EDAP 은(는) 수익성이 없으며 지난 5년 동안 연간 72% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 EDAP 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: EDAP 은(는) 수익성이 없어 지난 해 수익 성장을 Medical Equipment 업계( 2.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: EDAP 현재 수익성이 없기 때문에 마이너스 자본 수익률( -34.41% )을 갖습니다.

EDAP TMS 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 35%, revenue upgraded

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Price target increased by 12% to US$14.50

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

Consensus EPS estimates increase by 36%

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Now 20% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Consensus EPS estimates have been upgraded

Third quarter 2022 earnings released: EPS: €0 (vs €0.03 loss in 3Q 2021)

Now -35% undervalued

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP's Focal One Revenue Is Set To Accelerate

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Price target decreased to US$12.00

Consensus EPS estimates have been downgraded.

Full year 2021 earnings: EPS and revenues miss analyst expectations

EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022

EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers

Acceleration At EDAP

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Third quarter 2021 earnings released: €0.03 loss per share (vs €0.034 loss in 3Q 2020)

Price target decreased to US$11.50

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Mega Elektroniikka Oy agreed to acquire a 25% stake in Technomed Medical Systems S.A from EDAP TMS S.A. (NasdaqGM : EDAP).

Second quarter 2021 earnings released: €0.013 loss per share (vs €0.006 loss in 2Q 2020)